Clinical Trials | December 12, 2025
Neurizon’s ALS drug regimen cleared for launch in Healey platform trial
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The FDA aims to make a decision by April 8, 2026
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
The new centre brings advanced corneal procedures pioneered in India
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The new site marks the company’s first operation in the region
Subscribe To Our Newsletter & Stay Updated
